Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.48 |
| ▸ | ANPEP | P15144 | 4/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058842 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL699280 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL5691732 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL7805563 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL2252585 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL1154972 | 1.00 | MMP2 (0.48) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL8607697 | 0.92 | MMP2 (0.40) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL8609251 | 0.92 | MMP2 (0.40) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL25436769 | 0.88 | NR1H2 (0.43) | MMP2ANPEPNR1H2NR1H3PTPN1 | |
| SCHEMBL19898506 | 0.88 | NR1H2 (0.43) | MMP2ANPEPNR1H2NR1H3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092056-A1 | MELANOCORTIN-4 RECEPTOR AGONISTS | LG CHEMICAL LTD (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12516047-B2 | Melanocortin-4 receptor agonists | LG CHEM, LTD. (KR) | 2026-01-06 | — | — | US | disclosed |
| EP-4605386-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-07-31 | — | — | US | disclosed |
| US-20250179016-A1 | AMORPHOUS MELANOCORTIN-4 RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2025-06-05 | — | — | US | disclosed |
| EP-3853234-B1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119775187-A | Melanocortin-4 receptor agonists | 株式会社LG化学 | 2025-04-08 | — | — | CN | disclosed |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| US-5317016-A | Pyrrolidylthiocarbapenem derivative | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1994-05-31 | — | — | US | disclosed |
| US-5264453-A | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0289911-B1 | PYRROLIDINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-16 | — | — | EP | disclosed |
| WO-1993011128-A1 | AMINOALKYLPYRROLIDINYLTHIOCARBAPENEM DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-10 | — | — | WO | disclosed |
| EP-0545290-A1 | Aminoalkylpyrrolidinylthiocarbapenem derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0528678-A1 | A pyrrolidylthiocarbapenem derivative | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
| US-5130323-A | PYRROLIDINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-14 | — | — | US | disclosed |
| EP-0367130-A2 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-09 | — | — | EP | disclosed |
| US-4916152-A | THROMBOXANE A2 ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0289911-A2 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | MMP2 1455/4885ANPEP 539/4885NR1H2 449/4885 |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | MMP2 2585/4885ANPEP 1615/4885NR1H2 639/4885 |
| US-20260092056-A1 | MELANOCORTIN-4 RECEPTOR AGONISTS | MC5R, MC4R, MC3R | MMP2 2674/4885ANPEP 1620/4885NR1H2 1221/4885 |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | MMP2 3156/4885ANPEP 3268/4885NR1H2 2154/4885 |
| US-20250179016-A1 | AMORPHOUS MELANOCORTIN-4 RECEPTOR AGONIST | MC4R, MC3R, MC5R | MMP2 3876/4885ANPEP 1691/4885NR1H2 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.